Literature DB >> 11342779

Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy.

C M Herman1, M W Kattan, M Ohori, P T Scardino, T M Wheeler.   

Abstract

Gleason score (GS) is a powerful predictor of disease progression in men with prostate cancer (PCa). The majority of clinically localized prostate cancers, however, are moderately (GS5/6) or moderate to poorly (GS7) differentiated tumors with indeterminate prognosis. Differences in disease progression between patients with GS5/6 and GS7 tumors suggest the presence of any component of high-grade tumor (Gleason pattern [GP] 4/5) worsens prognosis markedly. Indeed, McNeal et al. have shown that quantification of GP4/5 provides prognostic information beyond the standard GS. Few investigators have analyzed whether primary and secondary GPs are important prognostically within GS7 PCa. All 823 whole-mount radical prostatectomy specimens with GS7 from a single surgeon (P.T.S.) were analyzed. Tumors were either 3+4 or 4+3, and primary GP was assigned by the same pathologist (T.M.W.). A total of 643 patients with 3+4 tumors and 180 patients with 4+3 tumors were studied. Statistical analysis using the log-rank test showed a significant difference in recurrence-free survival between patients with primary GP4 and those with GP3 (p <0.0001). However, in multivariate analysis with preoperative prostate-specific antigen, total tumor volume, surgical margin status, and the presence or absence of seminal vesicle involvement, extraprostatic extension, and lymph node metastasis, the primary GP did not retain independent significance (p = 0.0557). GS7 PCa is a heterogeneous group of tumors. In this cohort of men with GS7 tumors treated by radical retropubic prostatectomy, primary GP showed a significant correlation with other histologic and clinical predictors of disease progression; however, it was not independently predictive of disease progression in multivariate analysis (p = 0.76).

Entities:  

Mesh:

Year:  2001        PMID: 11342779     DOI: 10.1097/00000478-200105000-00014

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

1.  Detection of Local Recurrence with 3-Tesla MRI After Radical Prostatectomy: A Useful Method for Radiation Treatment Planning?

Authors:  Daniel Buergy; Metin Sertdemir; Anja Weidner; Mohamed Shelan; Frank Lohr; Frederik Wenz; Stefan O Schoenberg; Ulrike I Attenberger
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

2.  Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy.

Authors:  Andrew B Rosenkrantz; Michael J Triolo; Jonathan Melamed; Henry Rusinek; Samir S Taneja; Fang-Ming Deng
Journal:  J Magn Reson Imaging       Date:  2014-02-25       Impact factor: 4.813

3.  PSA/biparametric MRI: An accurate potential diagnostic approach for detection and management of local recurrence after radical prostatectomy.

Authors:  Maria Cristina Aisa; Irene Piscioli; Aldo Di Blasi; Michele Scialpi
Journal:  Turk J Urol       Date:  2020-01-01

Review 4.  Active surveillance in prostate cancer: the need to standardize.

Authors:  Xavier Filella; Juan Alcover; Rafael Molina
Journal:  Tumour Biol       Date:  2011-05-28

5.  Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence.

Authors:  Qi Long; Jianpeng Xu; Adeboye O Osunkoya; Soma Sannigrahi; Brent A Johnson; Wei Zhou; Theresa Gillespie; Jong Y Park; Robert K Nam; Linda Sugar; Aleksandra Stanimirovic; Arun K Seth; John A Petros; Carlos S Moreno
Journal:  Cancer Res       Date:  2014-04-08       Impact factor: 12.701

6.  Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors.

Authors:  Olivier Alenda; Guillaume Ploussard; Pascal Mouracade; Evanguelos Xylinas; Alexandre de la Taille; Yves Allory; Dimitri Vordos; Andras Hoznek; Claude Clement Abbou; Laurent Salomon
Journal:  World J Urol       Date:  2010-11-24       Impact factor: 4.226

7.  Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort.

Authors:  Jonathan L Wright; Claudia A Salinas; Daniel W Lin; Suzanne Kolb; Joseph Koopmeiners; Ziding Feng; Janet L Stanford
Journal:  J Urol       Date:  2009-12       Impact factor: 7.450

Review 8.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

9.  Prognostic Gleason grade grouping: data based on the modified Gleason scoring system.

Authors:  Phillip M Pierorazio; Patrick C Walsh; Alan W Partin; Jonathan I Epstein
Journal:  BJU Int       Date:  2013-03-06       Impact factor: 5.588

10.  Biochemical recurrence in Gleason score 7 prostate cancer in korean men: significance of the primary Gleason grade.

Authors:  Yun Kwan Ro; Sangchul Lee; Chang Wook Jeong; Sung Kyu Hong; Seok Soo Byun; Sang Eun Lee
Journal:  Korean J Urol       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.